


CORRECTION OPEN



Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAsTop2 trial

Hjalmar Flygt , Stina Söderlund, Johan Richter , Susanne Saussele , Perttu Koskenvesa, Leif Stenke, Satu Mustjoki , Andreja Dimitrijevic , Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen and Ulla Olsson-Strömberg

© The Author(s) 2024

Leukemia (2024) 38:925; <https://doi.org/10.1038/s41375-024-02184-z>

Correction to: *Leukemia* <https://doi.org/10.1038/s41375-024-02145-6> published online 26 January 2024

The information provided in the Figure III legend states:

“TFR probability at 6, 12 and 24 months was 62, 55 and 42% respectively”, the figure should have appeared as shown below:

“TFR probability at 6, 12 and 24 months was 61, 56 and 46%, respectively”



Open Access This article is licensed under a Creative Commons

Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024